Description
liquiCORE Guardant360 is a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a blood sample to identify genomic alterations in advanced solid tumors. It helps oncologists find targeted therapy options by detecting clinically relevant biomarkers. The test is FDA-approved as a companion diagnostic (CDx) for certain therapies and is used to guide treatment decisions in advanced cancer
Reviews
There are no reviews yet.